<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-20 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-20</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-20</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-7ba4125546f6478640b930ba1dd9f09c9b400955</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/7ba4125546f6478640b930ba1dd9f09c9b400955" target="_blank">Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial</a></p>
                <p><strong>Paper Venue:</strong> Nature Medicine</p>
                <p><strong>Paper TL;DR:</strong> Results from the PRADO extension cohort of the OpACIN-neo trial show that pathologic response rate to neoadjuvant ipilimumab and nivolumab can be used as a criterion for personalization of further treatment in stage III nodal melanoma, with the potential to reduce treatment morbidity and increase patient quality of life.</p>
                <p><strong>Cost:</strong> 0.033</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e20.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e20.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Personalized Response-Directed Surgery and Adjuvant Therapy after Neoadjuvant Ipilimumab and Nivolumab (PRADO)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multicenter phase 2, non-randomized extension cohort of OpACIN-neo that tested response-directed omission of therapeutic lymph node dissection (TLND) and adjuvant therapy after two cycles of neoadjuvant ipilimumab+nivolumab in resectable stage III nodal melanoma; pathologic response in the index lymph node (ILN) determined subsequent surgery and adjuvant therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO (OpACIN-neo extension cohort); ClinicalTrials.gov NCT02977052</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Reijers et al., Nature Medicine 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicenter phase 2, single-arm, non-randomized response-directed trial (PRADO, extension cohort of OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single neoadjuvant cohort: 2 cycles ipilimumab 1 mg/kg + nivolumab 3 mg/kg → ILN resection at week 6; subsequent treatment tailored to ILN pathologic response: MPR (≤10% viable tumor) → omit TLND and adjuvant; pPR (>10–≤50%) → TLND only; pNR (>50%) → TLND + adjuvant systemic therapy (nivolumab for BRAF WT or dabrafenib+trametinib for BRAF V600E/K) ± radiotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Adults with resectable clinical stage IIIb–IIId nodal melanoma, measurable nodal disease by RECIST v1.1 (≥15 mm short axis), normal LDH, ECOG 0–1; excluded prior CTLA-4/PD-1/PD-L1 CPI, prior BRAF/MEK, recent in-transit mets, autoimmune disease.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Clinical stage IIIb-d nodal melanoma, resectable nodal disease measurable by RECIST v1.1; inclusion required at least one measurable node; normal LDH; ECOG 0–1.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Single cohort with post-hoc pathologic subgroups: MPR n=60 (61%), pPR n=11 (11%), pNR n=21 (21%)</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab 1 mg/kg IV + nivolumab 3 mg/kg IV</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two cycles: day 0 and week 3; ILN (marked index node) resection planned at week 6</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>For pNR: adjuvant nivolumab (BRAF wild-type) or dabrafenib + trametinib (BRAF V600E/K) for 52 weeks ± local radiotherapy; MPR omitted adjuvant; pPR no adjuvant per protocol</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>ILN resection scheduled at week 6; median time from start of neoadjuvant CPI to TLND (for those who underwent TLND) was 9.6 weeks (range 8.1–22.1)</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>94/99 (95%) underwent ILN resection; marker retrieved in 90/94 (96%) at first attempt; ILN resection delayed in 3 patients due to irAEs; TLND delayed in 5 (16%) patients; 6% had ILN procedure delayed or cancelled due to irAEs overall.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>INMC criteria: pCR = 0% viable tumor; near-pCR = 1–≤10% viable; MPR defined as pCR + near-pCR (≤10% viable tumor); pPR = >10–≤50% viable; pNR = >50% viable.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>48/99 = 49% (pCR)</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>60/99 = 61% (MPR = pCR + near-pCR); overall pathologic response rate (pRR, pCR+near-pCR+pPR) = 71/99 = 72%</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Strong association: 24-month RFS for MPR = 93% (95% CI: 87–>99%); for pPR = 64% (95% CI: 41–99%); for pNR = 71% (95% CI: 55–94%). Authors report pathologic response strongly associated with prolonged RFS and DMFS; no HRs for subgroup comparisons reported.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response (primary), 24-month relapse-free survival (RFS), distant metastasis-free survival (DMFS), event-free survival (EFS), overall survival (OS); survival timepoints reported at 24 months and KM curves with median follow-up ~28.1 months.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>EFS for total population: 24-month estimate 80% (95% CI: 72–88%); no arm comparisons (single-arm).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Total cohort 24-month RFS 85% (95% CI: 78–92%); by ILN response: MPR 93% (95% CI: 87–>99%), pPR 64% (95% CI: 41–99%), pNR 71% (95% CI: 55–94%).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td>Total cohort 24-month OS 95% (95% CI: 91–99%); subgroup OS not mature/medians not reached.</td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td>Total cohort 24-month DMFS 89% (95% CI: 83–96%); by ILN response: MPR 98% (95% CI: 94–>99%), pPR 64% (95% CI: 41–99%), pNR 76% (95% CI: 60–97%).</td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td>No hazard ratios comparing neoadjuvant vs adjuvant or between subgroups reported in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>At 24 months: MPR RFS 93%, pPR RFS 64% (absolute difference MPR vs pPR = 29 percentage points), pNR RFS 71%. Total cohort RFS 85% at 24 months.</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up 28.1 months (IQR 25.0–33.8), minimum follow-up for patients alive 23.4 months.</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Baseline tumor PD-L1 tumor proportion score correlated with pathologic response (pRR 56% if PD-L1 <1%, 92% if 1–50%, 100% if >50%; P = 0.004). The paper cites preclinical and earlier clinical data supporting superior induction of anti-tumor immunity with neoadjuvant CPI but provides limited mechanistic new data in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Not reported in the main manuscript (no data on peripheral TCR expansion, cytokines or blood immune subsets presented).</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>PD-L1 expression in baseline tumor biopsies associated with pathologic response as above. No additional tumor immune microenvironment signatures (e.g., IFN-γ gene signatures) are reported in the main text.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td>Not reported in this report; authors refer to planned/ongoing genetic and transcriptomic investigations comparing ILN and recurrent nodes.</td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td>Not reported.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td>Baseline PD-L1 tumor proportion score (see PD-L1 association above). Presence of ≥2 PET-positive lymph nodes at baseline was enriched among the MPR patients who later recurred (all four MPR relapses had ≥2 PET-positive nodes and BRAF V600E). No TMB, TCR or IFN-signature data presented here.</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors state neoadjuvant ipilimumab + nivolumab induces high pathologic response rates and that pathologic response is strongly associated with prolonged RFS; they cite preclinical and early clinical data suggesting neoadjuvant CPI produces superior anti-tumor immunity and survival benefit compared to adjuvant CPI, and they hypothesize that MPR identifies patients who may safely omit TLND/adjuvant while pNR may benefit from escalation.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Grade 3–4 immune-related adverse events within first 12 weeks: 22/99 = 22% (95% CI: 14–32%). Most frequent grade 3–4 events within 12 weeks: ALT increased 7%, AST increased 6%, diarrhea 5%/colitis 4%; overall up to data cutoff 30% had grade 3–4 irAEs, serum lipase increase 9% (later events included).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td>No treatment-related deaths observed.</td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>Of 21 pNR patients, 17 received adjuvant systemic therapy; 4 did not (3 due to irAEs, 1 lost to follow-up). Among all patients, some skipped planned adjuvant therapy due to toxicity but precise overall adjuvant discontinuation rates beyond pNR group not tabulated.</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>TLND omission (ILN-only) associated with lower surgical morbidity: CTCAE surgical AE rate 46% (ILN-only, n=61) vs 84% (ILN+TLND, n=31) at week 12 (P < 0.001). Clavien–Dindo grades lower in ILN-only group (P < 0.001). TLND delayed in 5 (16%) patients; ILN resection delayed in 3 due to irAEs; no unexpected surgical complications reported.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>Exploratory: pathologic response not associated with baseline tumor burden or most demographics. PD-L1 expression associated with pathologic response. All 4 MPR relapses had ≥2 PET-positive nodes and BRAF V600E (signal of worse outcome within MPR). Small subgroup sizes limit inference.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td>MPR relapses were mostly regional (3 regional, one progressed to M1a later); pPR had more distant recurrences (3 distant, 1 regional→distant); pNR relapses included regional and distant disease. Salvage surgery and adjuvant therapy were effective for regional recurrences.</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td>Authors speculate CPI-resistant tumor subclones and genetic/transcriptomic differences between ILN and recurrent nodes as possible mechanisms; they report planned investigations but present no molecular evidence in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>Co-primary endpoint (predefined feasibility threshold for 24-month RFS in MPR) was not met per protocol because >1 recurrence occurred in MPR (4 recurrences), producing a 24-month RFS of 93% (protocol expected near 97%); pPR patients had worse outcomes than MPR, suggesting pPR should not be treated like MPR. Non-randomized design prevents direct comparison with adjuvant-only strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm, non-randomized design; relatively small numbers in pPR and pNR subgroups; indirect comparisons to historical controls; short-to-moderate follow-up (median 28.1 months) though many relapses occur within 12 months; possible sampling error since only ILN assessed (though prior data support concordance).</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td>Financial support from Bristol Myers Squibb; multiple authors disclosed advisory roles, consultancy fees, research funding from pharma companies (detailed in COI section).</td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>ClinicalTrials.gov NCT02977052</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e20.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo: Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A multicenter phase 2 randomized trial that tested different dosing schedules of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma and identified the two-cycle ipilimumab 1 mg/kg + nivolumab 3 mg/kg schedule as favorable (arm B) with high pathologic response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo; ClinicalTrials.gov NCT02977052 (parent registry shared with PRADO extension)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Lancet Oncology 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicenter phase 2 randomized controlled trial comparing different neoadjuvant dosing schedules of ipilimumab + nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Randomized arms with varying dosing schedules of ipilimumab + nivolumab; Arm B (ipilimumab 1 mg/kg + nivolumab 3 mg/kg x2) identified as most favorable.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Macroscopic stage III melanoma (resectable nodal disease); details referenced in OpACIN-neo publication.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III nodal melanoma (details in original OpACIN-neo report).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Various ipilimumab + nivolumab dosing schedules; favored schedule ipilimumab 1 mg/kg + nivolumab 3 mg/kg (two cycles).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two cycles (favored schedule) with surgery planned after neoadjuvant dosing (timing per protocol).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>In OpACIN-neo all patients proceeded to surgery and then adjuvant therapy per protocol (see original publication).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Pathologic response assessed by INMC criteria (pCR, near-pCR, pPR, pNR); paper cites pRRs from OpACIN-neo.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Reported pRR ~77% for the favored schedule (arm B) and grade 3–4 irAEs ~20% within first 12 weeks (reported in PRADO referencing OpACIN-neo).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>OpACIN-neo previously reported strong association between pathologic response and prolonged RFS (cited in PRADO); exact HRs not provided in PRADO text.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response, safety, and survival endpoints in original publication; PRADO references pRR and association with RFS.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>OpACIN-neo included biomarker analyses (referenced), and prior reports support association of pathologic response with survival; PRADO uses OpACIN-neo schedule as basis but does not recapitulate detailed mechanistic data here.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>OpACIN-neo data cited as evidence that combination anti-CTLA-4 + anti-PD-1 in neoadjuvant setting yields high pathologic responses and favorable outcomes compared to other schedules; PRADO adopted the favored schedule.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>OpACIN-neo arm B reported ~20% grade 3–4 irAEs (as cited in PRADO).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Referenced as prior trial informing PRADO; details in original publication.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>OpACIN-neo clinical registration details available in original paper (NCT02977052 referenced in PRADO)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e20.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An earlier clinical trial that compared neoadjuvant ipilimumab + nivolumab to adjuvant administration in macroscopic stage III melanoma and provided early clinical evidence that neoadjuvant therapy can induce superior anti-tumor immunity and improved outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN; ClinicalTrials.gov NCT02437279 (as referenced in PRADO)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Blank et al., Nature Medicine 2018</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2018</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Early clinical trial comparing neoadjuvant versus adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma (reported in Nat Med 2018).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Direct comparison between neoadjuvant ipilimumab + nivolumab and adjuvant-only ipilimumab + nivolumab in resectable stage III disease (details in original publication).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Macroscopic (clinically apparent) stage III melanoma; resectable nodal disease.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III (details in original publication).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab (dosing per original report).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant ipilimumab + nivolumab (per original report) for comparator arm</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant ipilimumab + nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>INMC pathology criteria used in neoadjuvant studies; PRADO cites OpACIN as evidence that neoadjuvant dosing induces pathologic responses associated with RFS.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Earlier reports (cited by PRADO) indicate high pathologic response rates in neoadjuvant arms (74–78% across OpACIN/OpACIN-neo/other trials).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>OpACIN reported that neoadjuvant treatment produced immunologic and clinical advantages compared with adjuvant delivery (cited in PRADO); specific HRs not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response and survival endpoints (see original manuscript).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>OpACIN provided early clinical evidence of superior immune priming with neoadjuvant CPI versus adjuvant, cited by PRADO as mechanistic rationale; detailed immune correlates are reported in OpACIN publications (referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Cited claim: neoadjuvant CPI leads to superior anti-tumor immunity and survival benefit compared to adjuvant CPI (based on OpACIN data).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Referenced as early clinical evidence; see original publication for trial-specific limitations.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>OpACIN ClinicalTrials.gov NCT02437279 (referenced in PRADO)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e20.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Liu2016 (preclinical)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease (preclinical mouse models)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Preclinical study in murine models reporting superior efficacy of neoadjuvant compared with adjuvant immune checkpoint blockade for eradication of metastatic disease, cited as mechanistic evidence supporting neoadjuvant approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Liu et al., Cancer Discovery 2016</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2016</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Preclinical (murine) translational study comparing timing of immunotherapy (neoadjuvant versus adjuvant) in metastatic models</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Preclinical comparison of neoadjuvant versus adjuvant immune checkpoint blockade in mouse models of metastatic cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Not applicable (animal models).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Preclinical CPI regimens (details in original paper).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant CPI in comparator groups (preclinical).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant CPI (preclinical comparator)</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Preclinical data suggested improved eradication of metastases and survival with neoadjuvant CPI; PRADO cites this as supporting rationale.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Preclinical endpoints (metastasis eradication, survival in mice); translational relevance cited.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Preclinical mechanistic data support that neoadjuvant exposure primes systemic anti-tumor immunity more effectively than same therapy given post-resection; PRADO cites as mechanistic rationale.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td>Preclinical studies often report increased systemic tumor-specific T cell responses after neoadjuvant therapy (details in original paper).</td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>Preclinical models show differences in intratumoral immune activation when therapy given preoperatively (see original paper).</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Cited claim: neoadjuvant CPI leads to superior anti-tumor immunity and survival in preclinical models, providing mechanistic rationale for clinical neoadjuvant trials.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Preclinical models may not fully recapitulate human tumor heterogeneity and immune environment; cited as supportive but not definitive.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e20.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801 (randomized phase 2): Neoadjuvant + adjuvant pembrolizumab versus adjuvant pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase 2 trial in clinical stage III–IV melanoma comparing neoadjuvant plus adjuvant pembrolizumab versus adjuvant pembrolizumab alone; cited in PRADO as an ongoing randomized trial addressing the benefit of neoadjuvant CPI versus adjuvant-only.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>SWOG S1801 (NCT03698019) randomized phase 2 trial comparing neoadjuvant plus adjuvant pembrolizumab versus adjuvant pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>SWOG S1801; ClinicalTrials.gov NCT03698019</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Randomized phase 2 trial (mentioned in PRADO; details in SWOG S1801 protocol/publications).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant pembrolizumab followed by surgery and adjuvant pembrolizumab versus surgery followed by adjuvant pembrolizumab (adjuvant-only).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Clinical stage III–IV melanoma (mentioned), trial includes resectable disease; details in trial registry/publications.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Clinical stage III–IV as per trial protocol (see registry).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab (neoadjuvant dosing per trial protocol).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant pembrolizumab in both arms (timing/duration per protocol), with neoadjuvant arm receiving additional preoperative doses.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant pembrolizumab alone (control arm).</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Designed to compare event-free or relapse-free outcomes between neoadjuvant+adjuvant vs adjuvant-only (details in trial publications).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>SWOG S1801 is intended to generate translational immune correlative data comparing timing of PD-1 blockade; PRADO references it as an important randomized test of neoadjuvant benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Mentioned by PRADO as an ongoing randomized phase 2; no results or limitations discussed in PRADO.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>ClinicalTrials.gov NCT03698019</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e20.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NADINA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NADINA: Randomized phase 3 trial of standard TLND + adjuvant nivolumab versus neoadjuvant ipilimumab + nivolumab followed by TLND and adjuvant nivolumab or BRAF/MEK in stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A randomized phase 3 trial (NCT04949113) mentioned in PRADO that is testing standard immediate TLND followed by adjuvant nivolumab versus a neoadjuvant ipilimumab+nivolumab approach followed by TLND and adjuvant therapy (with non-MPR patients receiving adjuvant nivolumab or BRAF/MEK inhibition).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>NADINA (NCT04949113): randomized comparison of standard TLND + adjuvant nivolumab versus neoadjuvant ipilimumab + nivolumab followed by TLND and adjuvant nivolumab or BRAF/MEK inhibition</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NADINA; ClinicalTrials.gov NCT04949113</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Randomized phase 3 trial (mentioned in PRADO as ongoing at time of PRADO publication)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Arm A: standard TLND followed by adjuvant nivolumab; Arm B: neoadjuvant ipilimumab + nivolumab → TLND → adjuvant nivolumab (and non-MPR receive BRAF/MEK if mutant) — tests neoadjuvant strategy vs standard surgery-first approach.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Clinical stage III melanoma; NADINA includes patients with in-transit metastases (unlike many prior neoadjuvant trials).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Clinical stage III (includes in-transit metastases per PRADO description).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab + nivolumab (neoadjuvant dosing per NADINA protocol).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant nivolumab (and BRAF/MEK inhibition for non-MPR BRAF-mutant patients) as per NADINA protocol.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Standard TLND followed by adjuvant nivolumab (surgery-first arm).</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Presumably INMC pathologic response criteria used—PRADO references NADINA but does not detail pathologic endpoints.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>NADINA will compare outcomes between a neoadjuvant strategy and standard surgery-first approach; PRADO notes it will define benefit of neoadjuvant systemic CPI versus standard care.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>NADINA expected to include translational correlates; PRADO mentions it as important ongoing phase 3 trial but provides no mechanistic data.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>ClinicalTrials.gov NCT04949113</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e20.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e20.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>INMC pooled analysis (Menzies 2021)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Pooled analysis from INMC showing that pathologic response after neoadjuvant therapy is associated with improved survival in melanoma; cited by PRADO to support using pathologic response as a surrogate/stratification biomarker.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Menzies et al., Nature Medicine 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Pooled translational/clinical analysis (INMC) aggregating neoadjuvant trial data to relate pathologic response to survival outcomes</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Pooled datasets from neoadjuvant melanoma trials; analyses focused on pathologic response and survival associations rather than randomized treatment comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Aggregated resectable melanoma patients from multiple neoadjuvant trials; specifics in original paper.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage III/IV resectable disease per source trials included in the consortium analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Heterogeneous across pooled trials (various neoadjuvant CPI regimens).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>INMC pathologic response criteria applied across pooled datasets (pCR, near-pCR, pPR, pNR).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Pooled analysis supports that pathologic response after neoadjuvant therapy strongly associates with improved RFS/EFS/OS; cited by PRADO to justify response-directed approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response correlated with survival endpoints across pooled cohorts (details in Menzies et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>INMC pooled work includes translational analyses associating pathologic response with favorable outcomes; PRADO references this as external supportive evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Pooled data used to justify pathologic response as prognostic and to motivate response-directed treatment tailoring in PRADO.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Pooled analyses combine heterogeneous trials with differing regimens and definitions; see original INMC paper for details.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial', 'publication_date_yy_mm': '2022-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease <em>(Rating: 2)</em></li>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma <em>(Rating: 2)</em></li>
                <li>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial <em>(Rating: 2)</em></li>
                <li>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma <em>(Rating: 2)</em></li>
                <li>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>